Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „dosing“
Suchtreffer
Begriffe & Kennungen
Aclasta · 4.8 · In clinical trials in osteoporosis, the change in creatinine clearance (measured annually prior to dosing) and
Eintrag öffnenAldara · 4.8 · In the pivotal trials with 3 times a week dosing, the most frequently reported adverse drug reactions judged t
Eintrag öffnenAldara · 4.8 · In trials with 5 times per week dosing 58% of patients experienced at least one adverse event. The most freque
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.5 · In a clinical study in healthy volunteers, steady-state dosing with ambrisentan 10 mg once daily did not signi
Eintrag öffnenAptivus · 4.5 · Antacids aluminium- and Tipranavir Cmax ↓ 25% Dosing of Aptivus, co- magnesium-based antacid Tipranavir AUC ↓
Eintrag öffnenBeovu · 4.8 · DME After dosing with Beovu for 96 weeks, treatment-emergent anti-brolucizumab antibodies were detected in 16-
Eintrag öffnenBeovu · 4.8 · Wet AMD After dosing with Beovu for 88 weeks, treatment-emergent anti-brolucizumab antibodies were detected in
Eintrag öffnenBimzelx · 4.8 · Approximately 31% of patients with psoriatic arthritis treated with bimekizumab at the recommended dosing regi
Eintrag öffnenBimzelx · 4.8 · Approximately 44% of patients with AS treated with bimekizumab up to 52 weeks at the recommended dosing regime
Eintrag öffnenBimzelx · 4.8 · Approximately 57% of patients with nr-axSpA treated with bimekizumab up to 52 weeks at the recommended dosing
Eintrag öffnenBimzelx · 4.8 · Approximately 59% of HS patients treated with bimekizumab up to 48 weeks at the recommended dosing regimen (32
Eintrag öffnenBiomarker, Pharmakologische
Eintrag öffnenCarvykti · 4.8 · Prolonged and recurrent cytopenias Grade 3 or 4 cytopenias at Day 1 after dosing, not resolved to Grade 2 or l
Eintrag öffnenCarvykti · 4.8 · Table 5 lists the incidences of Grade 3 or Grade 4 cytopenias occurring after dosing not resolved to Grade 2 o
Eintrag öffnenCerdelga · 4.5 · At 84 mg once daily dosing with eliglustat in PMs, it is predicted that concomitant use of moderate CYP3A inhi
Eintrag öffnenCerdelga · 4.5 · At 84 mg twice daily dosing with eliglustat in non-PMs, it is predicted that concomitant use of moderate CYP2D
Eintrag öffnenCerdelga · 4.5 · At 84 mg twice daily dosing with eliglustat in non-PMs, it is predicted that concomitant use of moderate CYP3A
Eintrag öffnenCerdelga · 4.5 · CYP2D6 inhibitors used simultaneously with CYP3A inhibitors In IMs and EMs At 84 mg twice daily dosing with el
Eintrag öffnenCerdelga · 4.5 · CYP3A inhibitors in PMs At 84 mg once daily dosing with eliglustat in PMs, it is predicted that concomitant us
Eintrag öffnenCibinqo · 4.8 · 12 Venous thromboembolism Among all patients treated in clinical studies with consistent dosing regimens of ei
Eintrag öffnen